74 related articles for article (PubMed ID: 29361925)
1. Case report: Successful sequential therapy of crizotinb and entrectinib in ROS1-positive non-small-cell lung cancer with brain metastasis in later-settings.
Dong W; Zhuge J; Yu P; Liu K; Yang M; Wang H
Medicine (Baltimore); 2023 Dec; 102(51):e36591. PubMed ID: 38134118
[TBL] [Abstract][Full Text] [Related]
2. Entrectinib Response to ROS1-Fusion-Positive Non-Small-Cell Lung Cancer That Progressed on Crizotinib with Leptomeningeal Metastasis: A Case Report.
Sawada H; Taniguchi Y; Iizuka S; Ikeda T; Aga M; Hamakawa Y; Miyazaki K; Misumi Y; Agemi Y; Nakamura Y; Maeda K; Shimokawa T; Okamoto H
Case Rep Oncol; 2023; 16(1):1558-1567. PubMed ID: 38089732
[TBL] [Abstract][Full Text] [Related]
3. A Novel Intergenic Region (chr2: 30,316,870)-
Zhou D; Ying J; Hu S; Li J; Liu H
Onco Targets Ther; 2024; 17():261-265. PubMed ID: 38558847
[TBL] [Abstract][Full Text] [Related]
4. Rapid Response to Lorlatinib in a Patient With TFG-ROS1 Fusion Positive Inflammatory Myofibroblastic Tumor of the Chest Wall Metastatic to the Brain and Refractory to First and Second Generation ROS1 Inhibitors.
Carcamo B; Bista R; Wilson H; Reddy P; Pacheco J
J Pediatr Hematol Oncol; 2021 Jul; 43(5):e718-e722. PubMed ID: 34157012
[TBL] [Abstract][Full Text] [Related]
5. Remarkable response to third-generation EGFR-TKI plus crizotinib in a patient with pulmonary adenocarcinoma harboring EGFR and ROS1 co-mutation: a case report.
Wu Z; Zhang Z; Zhang D; Li Z
Front Oncol; 2024; 14():1357230. PubMed ID: 38476366
[TBL] [Abstract][Full Text] [Related]
6. Effective Treatment with Cabozantinib in an Advanced Non-Small-Cell Lung Cancer Patient Harboring a
Wang G; Gao J; Lv J; Chen X; Wu J; Wang R; Jiang J
Onco Targets Ther; 2020; 13():1171-1177. PubMed ID: 32103985
[TBL] [Abstract][Full Text] [Related]
7. Effect of hyperthermia on intestinal microecology, immune function, and progression-free survival in patients with advanced unresectable lung adenocarcinoma.
Tian J; Long L; Zang J; Liu W; Liu P; Zhao L; Liang X; Xiao J
Sci Rep; 2023 Oct; 13(1):17223. PubMed ID: 37821661
[TBL] [Abstract][Full Text] [Related]
8. Lung adenocarcinoma patients with
Peng Y; Ernani V; Liu D; Guo Q; Hopps M; Cappelleri JC; Gupta R; de Andrade M; Chen J; Yi ES; Yang P
Heliyon; 2024 Apr; 10(7):e28285. PubMed ID: 38560203
[TBL] [Abstract][Full Text] [Related]
9. A Case of Lung Adenocarcinoma Harboring a Rare
Zhang M; Zhou H; Liu D; Yu R; Chen J
JTO Clin Res Rep; 2021 Feb; 2(2):100106. PubMed ID: 34589983
[TBL] [Abstract][Full Text] [Related]
10. Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.
Lin JJ; Zhu VW; Yoda S; Yeap BY; Schrock AB; Dagogo-Jack I; Jessop NA; Jiang GY; Le LP; Gowen K; Stephens PJ; Ross JS; Ali SM; Miller VA; Johnson ML; Lovly CM; Hata AN; Gainor JF; Iafrate AJ; Shaw AT; Ou SI
J Clin Oncol; 2018 Apr; 36(12):1199-1206. PubMed ID: 29373100
[TBL] [Abstract][Full Text] [Related]
11. Crizotinib, an Effective Agent in
Joshua JM; Kd S; K P; Vijayan M
Clin Med Insights Case Rep; 2018; 11():1179547617749615. PubMed ID: 29371790
[TBL] [Abstract][Full Text] [Related]
12. Next Generation Sequencing Reveals a Synchronous Trilateral Lung Adenocarcinoma Case with Distinct Driver Alterations of EGFR 19 Deletion or EGFR 20 Insertion or EZR-ROS1 Fusion.
Zhang X; Feng J; Su X; Lei Y; Wu W; Cheng X
Onco Targets Ther; 2020; 13():12667-12671. PubMed ID: 33328738
[TBL] [Abstract][Full Text] [Related]
13. EZR-ROS1 fusion renal cell carcinoma mimicking urothelial carcinoma: report of a previously undescribed gene fusion in renal cell carcinoma.
Tatjana A; Tjota MY; O'Donnell PH; Eggener SE; Agarwal PK; Haridas R; Segal J; Wang P
Virchows Arch; 2022 Feb; 480(2):487-492. PubMed ID: 34128116
[TBL] [Abstract][Full Text] [Related]
14. Interstitial Deletions Generating Fusion Genes.
Panagopoulos I; Heim S
Cancer Genomics Proteomics; 2021; 18(3):167-196. PubMed ID: 33893073
[TBL] [Abstract][Full Text] [Related]
15. Identification of a Combined RNA Prognostic Signature in Adenocarcinoma of the Lung.
He SY; Xi WJ; Wang X; Xu CH; Cheng L; Liu SY; Meng QQ; Li B; Wang Y; Shi HB; Wang HJ; Wang ZZ
Med Sci Monit; 2019 May; 25():3941-3956. PubMed ID: 31132294
[TBL] [Abstract][Full Text] [Related]
16. Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report.
Dong L; Xia J; Zhang J; Zhang Y; Zhu N; Zhang P; Zhang Y; Zhang X; Li S
BMC Pulm Med; 2018 Jan; 18(1):13. PubMed ID: 29361925
[TBL] [Abstract][Full Text] [Related]
17. Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
Xu H; Zhang Q; Liang L; Li J; Liu Z; Li W; Yang L; Yang G; Xu F; Ying J; Zhang S; Wang Y
Cancer Med; 2020 May; 9(10):3328-3336. PubMed ID: 32168429
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
